Disc Medicine highlights bitopertin Phase 3 EPP program in corporate presentation
IRON•Phase 2 AURORA results highlighted
Phase 2 AURORA highlighted a 40% PPIX reduction versus baseline, a 75% drop in phototoxic reactions versus placebo, and 86% of patients reporting “much better.”
Pipeline focus on heme and iron biology
Pipeline focus remains on heme and iron biology, including selcodebart for anemia indications, plus DISC-3405 for polycythemia vera and sickle cell disease.
Phase 3 APOLLO readout expected in Q4 2026
Disc Medicine released an investor presentation outlining late-stage plans for bitopertin in erythropoietic protoporphyria, with the Phase 3 APOLLO readout expected in Q4 2026.
APOLLO enrolled 183 EPP or XLP patients ages 12 and older in a 6-month, randomized, double-blind, placebo-controlled trial using a 60 mg dose.
The co-primary endpoints target pain-free sunlight exposure in month 6, plus percentage change in whole-blood metal-free PPIX at 6 months.
